Navigation Links
CuraGen Provides Update on Velafermin, Belinostat and CR011-vcMMAE Clinical Development Programs
Date:8/19/2007

mid-October 2007

Belinostat II Peripheral T- IV monotherapy Updated results

cell lymphoma anticipated Q4 2007

Belinostat II Cutaneous T- IV monotherapy Updated results

cell lymphoma anticipated Q4 2007

Belinostat II Ovarian cancer IV with Updated results

carboplatin anticipated Q4 2007

and paclitaxel

Belinostat I Solid tumors Oral Results anticipated Q4

2007

CR011- I/II Metastatic IV monotherapy Results anticipated Q4

vcMMAE melanoma 2007

About CuraGen

CuraGen Corporation (Nasdaq: CRGN) is a dedicated clinical-stage biopharmaceutical company developing diverse approaches, including novel protein, antibody, antibody-drug conjugate and small molecule therapeutics for the treatment of cancer and for cancer supportive care. CuraGen is currently conducting clinical trials to investigate the potential of velafermin, belinostat and CR011-vcMMAE. By leveraging the drug development strengths cultivated over the years, CuraGen expects to make a difference by advancing its promising therapeutics to address the unmet medical needs of cancer patients. CuraGen Corporation is headquartered in Branford, Connecticut. For additional information please visit http://www.curagen.com.

Safe Harbor

Statements in this press release regarding management's future expectations, beliefs, intentions, goals
'/>"/>

SOURCE CuraGen Corporation

Copyright©2007 PR Newswire.

0

GOOD

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. CuraGen Presents Update on Clinical Development Program for Belinostat
2. CuraGen and TopoTarget Announce New Clinical Results With Belinostat to be Reported at Upcoming Major Medical Meetings
3. CuraGen Announces New Preclinical Results with Belinostat and Velafermin to be Presented at AACR Annual Meeting
4. Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types
5. Liraglutide provides significantly better glucose control than insulin glargine in phase 3 study
6. XTL Provides Update on Phase I Clinical Trial of XTL-2125
7. Cervarix, the GSK Cervical Cancer Candidate Vaccine, Provides Sustained Immune Response in 100 Percent of Women up to 55 Years of Age
8. Daytrana (methylphenidate transdermal system) Provides Significant Effectiveness in ADHD Symptom Relief in Both Boys and Girls
9. DURECT Provides an Update to the Memryte Program Under Development by Voyager Pharmaceutical Corp
10. NicOx Provides an Update on the Phase 2a Study for NCX 1000 Conducted With Axcan
11. Indivumed Study Provides Sound Scientific Basis for a Predictive Drug Test- Platform
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Anesiva Completes Sale of its Zingo(TM) Assets to Powder Pharmaceuticals and Lee's Pharmaceuticals 2SRI International Receives National Institutes of Health Grants to Develop Improved Tomographic Imaging Technology 2SRI International Receives National Institutes of Health Grants to Develop Improved Tomographic Imaging Technology 3Parascript Signature Verification Technology Used by Moscow Law Firm to Detect Signature Fraud in 24160 000 Debt Collection Case 9226 1Parascript Signature Verification Technology Used by Moscow Law Firm to Detect Signature Fraud in 24160 000 Debt Collection Case 9226 2Parascript Signature Verification Technology Used by Moscow Law Firm to Detect Signature Fraud in 24160 000 Debt Collection Case 9226 3Innerscope Research Adds to Its Advisory Board Two Pioneers in the Measurement and Application of Emotional Engagement 9224 1Innerscope Research Adds to Its Advisory Board Two Pioneers in the Measurement and Application of Emotional Engagement 9224 2Kornberg Associates Architects Selected to Develop Design for New Stanford University Imaging Center 9222 1Kornberg Associates Architects Selected to Develop Design for New Stanford University Imaging Center 9222 2